Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
KDventures AB ( ($SE:KDV.B) ) has issued an announcement.
KDventures’ portfolio company SVF Vaccines has entered a collaboration with UK-based biotechnology firm Touchlight to accelerate the development of SVF-001, a novel hepatitis B/D immunotherapy candidate. SVF-001 is designed to induce both neutralizing antibody and T-cell responses against key viral targets, positioning it as a potentially differentiated approach in the treatment of chronic hepatitis B/D infections.
Under the agreement, SVF Vaccines will use Touchlight’s proprietary doggybone DNA (dbDNA) platform, a cell-free, high-purity DNA manufacturing technology intended to enable rapid and scalable production. The partnership is expected to streamline SVF-001’s path toward clinical development and underscores KDventures’ strategic role as a 33 percent owner in SVF Vaccines, potentially enhancing the value and maturity of its life science investment portfolio.
More about KDventures AB
KDventures AB is a Nordic life sciences investment company listed on Nasdaq Stockholm that focuses on innovative pharmaceutical projects and medical technology products emerging from leading research institutions in the Nordic region. Through a diversified portfolio spanning multiple development stages and active board involvement, the firm aims to create value from early research through to commercialization, offering investors exposure to both listed and private life science assets with high growth potential.
Average Trading Volume: 1,504,338
Technical Sentiment Signal: Sell
Current Market Cap: SEK170.3M
See more insights into KDV.B stock on TipRanks’ Stock Analysis page.